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Abstract We report on a generic method to detect and iden-
tify the molecular profile of exosomes either derived from
cultured cell lines or isolated from biofluids. Exosomes are
nanovesicles shed by cells into their microenvironment and
carry the molecular identity of their mother cells. These vesi-
cles are actively involved in intercellular communication un-
der physiological conditions and ultimately in the spread of
various diseases such as cancer. As they are accessible in most
biofluids (e.g., blood, urine, or saliva), these biological entities
are promising tools for cancer diagnostics, offering a non-
invasive and remote access to the molecular state of the dis-
ease. The composition of exosomes derived from cancer cells
depends on the sort and state of the tumor, requiring a screen-
ing of multiple antigens to fully characterize the disease. Here,
we exploited the capacity of surface plasmon resonance bio-
sensing to detect simultaneously multiple exosomal and can-
cer biomarkers on exosomes derived from breast cancer cells.
We developed an immunosensor surface which provides
efficient and specific capture of exosomes, together with their
identification through their distinct molecular profiles. The
successful analysis of blood samples demonstrated the suit-
ability of our bioanalytical procedure for clinical use.
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Introduction
Molecular diagnostics aims to assess the pathophysiological
conditions of the patient by primarily targeting both nucleic
acids and proteins. Alterations in protein expression or func-
tion together with nucleic acid mutations or copy number
changes are the principal molecular indicators of a disease.
Identifying these biomarkers in cancer patients can provide
precious information on both the prognosis of the disease
and the predictive outcome of a given therapy [1]. Generally,
a single biomarker will not be sufficient for a reliable diagno-
sis as cancer is a highly heterogeneous disease with multiple
stages and subtypes reflected by multiple molecular abnor-
malities [2, 3]. Hence, a set of biomarkers describing both
the genome and proteome is fundamental to fully characterize
the tumor profile and pave the way for the development of a
highly specific and reproducible diagnostic test [4]. In that
context, single exosomes are promising candidates as they
transport the molecular identity of their mother cells. These
nanometer-sized containers of endosomal origin are released
by cells through the fusion of multivesicular bodies with the
plasma membrane. This secretion is modulated by environ-
mental stress leading to concentration variation in body fluids
such as blood, urine, or breast milk [5]. Exosomes play a
central role in the intercellular communication and, thereby,
also in the propagation of diverse pathologies, in primis cancer
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[6] and inflammatory [7] and neurodegenerative [8] diseases,
by activating signaling cascades in/or delivering bioactive
molecules such as lipids, proteins, or RNAs to the recipient
cells. Exosome isolation followed by bioanalysis would en-
able a non-invasive and remote biopsy of the tumor mass.
Considerable efforts are presently undertaken to identify and
screen exosomal cell surface receptors with the help of diverse
analytical tools. For example, proteomic analysis is mainly
performed by immunoassays [9] and mass spectrometry
[10], which are time-consuming techniques requiring large
amount of exosomes and are thus not suitable for clinical
applications. On the other hand, surface-sensitive techniques
have emerged as powerful and robust tools for characterizing
biomolecular interactions [11–13]. A striking example is the
surface plasmon resonance (SPR) biosensor which has be-
come a gold standard for the real-time and label-free monitor-
ing of biomolecular interactions [14, 15]. A SPR biosensor
exploits the evanescent surface plasmon wave at the surface
of a gold layer to probe the optical properties of the contacting
dielectric region and thereby quantifies changes in the number
of biomolecules at the sensor surface induced by molecular
interactions. Selective functionalization of the sensor gold sur-
face with capturing agents (e.g., antibodies, ligands, and
nucleic acids) enables the determination of the thermodynam-
ics (binding constants) and kinetics (rate constants) of specific
molecular interaction reactions. The versatility of SPR allows
the measurement of a broad range of biological targets for
various applications. For instance, SPR has been extensively
used for high-throughput screening of biological active com-
pounds [16], discovering novel biomolecular interactions [17]
and investigating dynamic processes involved in signaling
pathways [18, 19]. Moreover, complex biological fluids
(e.g., blood and urine) are compatible with SPRwhich renders
this technique attractive for quantitative analyses in clinical
laboratories [20], such as for Alzheimer’s disease [21], viruses
[22], infection-related antibodies [23], and cancer [24–26].
Only recently SPR has shown its potential in the field of
exosome research. Exosome concentration and screening of
membrane proteins were determined with commercial SPR
instruments [27, 28], while a larger molecular profiling of
exosomes derived from both culture cell lines and cancer pa-
tients has been performed with a miniaturized SPR device
based on nano-plasmonic holes [29]. In a continuation of these
studies, we have implemented this technique in the particular
clinical case of breast cancer. We have analyzed by SPR
exosomes isolated from three cultured cell lines of human
breast cancer, namely MCF-7, BT-474, and MDA-MB-231,
each of these cell lines representing a different class of breast
carcinoma, luminal A, luminal B, and claudin-low, respective-
ly [30]. The detection of the relative low concentration of the
biomarkers was only possible after we developed a suitable
sensor surface, drastically reducing nonspecific binding while
optimizing the sensitivity and stability for the specific signal.
Various cancer and exosomal biomarkers were targeted, lead-
ing to a characteristic molecular signature for each cell line.
For assessing the clinical applicability and usability of our
biosensor, we analyzed exosomes isolated from whole blood.
Themethodology is readily implementable in any academic or
clinical laboratory and would provide a unique fingerprint of
the status of a particular disease based on the exosomal protein




Dulbecco’s phosphate-buffered saline (D-PBS, Sigma),
DMEM/F-12+ GlutaMAX (Life Technologies), Newborn Calf
Serum (NBCS, Life Technologies), α-mercapto-ω-carboxy-
PEG3000 (long PEG, n=68, Sigma), PEG acid disulfide (short
PEG, n=7, Sigma), neutravidin (Thermo Scientific), N-ethyl-
N′-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDC,
Sigma), N-hydroxysuccinimide (NHS, Sigma), ethanolamine
(Sigma), and sodium dodecyl sulfate (SDS, Sigma).
Cell culture
MDA-MB-231, MCF-7, and BT-474 human breast cancer
cells (kind gift from Prof. C. Brisken, EPFL, Switzerland)
were grown in medium supplemented with 10 % NBCS (un-
less otherwise stated) in a humidified 5 % CO2 atmosphere at
37 °C.
Isolation of exosomes
Exosomes from cultured breast cancer cell lines were isolated
using a previously published protocol [31] with slight modi-
fications. Briefly, the conditioned medium (CM) of ∼40×106
cultured cells, maintained in serum-free medium during the
last 48 h, was first centrifuged at 300g for 4 min and then
filtered through a 0.22-μm pore-sized filter. Exosomes were
concentrated by ultrafiltration (UF) using a 100-kDa molecu-
lar weight cutoff (MWCO) Amicon Ultra-15 centrifugal filter
unit (Millipore) resuspended in D-PBS and concentrated again
by UF to a volume of approximately 250 μl. Exosomes were
further purified by size exclusion chromatography (SEC)
using a Sephacryl 500 10/40 GL column (GE Healthcare)
equilibrated in D-PBS with an ÄKTA-Purifier system (GE
Healthcare). Exosome-containing fractions were identified
by absorption at λ=280 nm and concentrated to the desired
volume with a 100-kDa MWCO Amicon Ultra-4 centrifugal
filter unit (Millipore). For exosome isolation from clinical
samples, plasma was obtained from healthy volunteers from
the Laboratoire de Recherche sur les Produits Sanguins,
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Lausanne, Switzerland. Five hundred microliters of plasma
was centrifuged at 300g for 4 min, filtered through a
0.22-μm pore-sized filter, and then purified by SEC using
the aforementioned procedure.
Size distribution of exosomes by DLS
Experiments were carried out on a Zetasizer Nano ZS
(Malvern) equipped with a He–Ne laser of 633 nm (4 mW),
and the light scattering from the samples was measured at an
angle of 175° to the incident laser beam. A typical experiment
comprised a sequence of 12×10 s recordings which were
repeated three times.
Cryo-EM
Exosomes were processed for visualization by cryo-EM as
previously described [31].
Molecular screening by SPR
Experiments were carried out on a Biacore 3000 instrument
(GE Healthcare) with D-PBS as running buffer at a flow rate
of 5 μl/min, unless otherwise stated. The gold-coated sensor
surfaces (SIA Kit AU, GE Healthcare) were first cleaned in
piranha solution (H2SO4/H2O2, 3:1) for 30 min at 50 °C,
rinsed extensively with distilled water and ethanol, and finally
dried under a stream of nitrogen. A self-assembled monolayer
of carboxylated polyethylene glycol (PEG) polymers was then
formed on the gold surfaces by overnight immersion in an
ethanolic solution containing 2 mM of 99 mol % short PEG
and 1 mol % long PEG. Unbound PEGs were removed by
1 min sonication in fresh ethanol. The gold surface was then
dried under a stream of nitrogen, mounted on the sensor chip
support, and docked into the Biacore 3000. Neutravidin was
covalently coupled to carboxylated PEGs using standard
amine coupling procedure by injecting the reagents in the
following order: 35 μl 0.05 M NHS/0.2 M EDC mixture,
60 μl neutravidin at 100 μg/ml in 10 mM acetic acid
(pH 4.5), and 35 μl 0.1 M ethanolamine. Unbound proteins
were removed upon injection of 4× 100 μl SDS 0.05 % at
100 μl/min. The amount of immobilized neutravidin was
approximately 2500 RU. Biotinylated antibodies (Electronic
Supplementary Material (ESM) Table S1) were diluted in
D-PBS at a concentration of 0.05 mg/ml, and 15 μl of
these solutions was injected over the neutravidin-coated
surface, reaching typical immobilization levels of 2000 RU.
Exosome solutions were finally injected sequentially for 4 min
over the antibody-functionalized surface. BiaEvaluation
Software Version 4.1 (Biacore) and IGOR Pro Version
6.34A (Wavemetrics) were used for data processing.
Sensorgrams were corrected for bulk refractive index changes
and nonspecific binding by subtracting the negative control
signal. Themolecular fingerprints were obtained byweighting
maximal responses with the respective antibody surface
coverage and normalized to anti-CD63 responses.
Molecular screening by ELISA
Exosomes were directly coated on the surface of a 96-well
plate (Greiner). Fifty microliters/well of purified exosome so-
lution was added and incubated overnight at 4 °C. The plate
was washed with D-PBS and blocked with 100 μl/well of
blocking solution (D-PBS containing 5 % BSA) at room tem-
perature for 1.5 h. Following three washes of D-PBS, 50 μl/
well of primary antibodies at 2 μg/ml in blocking solution
were added for 1 h at room temperature (RT). After three
washes of D-PBS, the plate was incubated with 50 μl/well
of HRP-conjugated anti-mouse IgG antibody (Sigma, 1:10,
000 dilution) in blocking solution for 1 h at RT. The wells
were finally washed three times. HRP-bound antibodies were
detected by adding 100 μl of 3,3′,5,5′-tetramethylbenzidine
(TMB, Sigma) solution, and the reaction was stopped with
100 μl 2 M H2SO4 after 30 min. The optical densities were
recorded at 450 nm using the multiwell plate reader
SpectraMax 360 (Molecular Devices).
Results and discussion
Purification and characterization of exosomes
Exosomes shed by the three breast cancer cell lines, MCF-7,
BT-474, and MDA-MB-231, were isolated from cell debris
and large particles by filtration using a 0.22-μm pore-sized
filter and subsequently concentrated by ultrafiltration (UF)
over a 100-kDa molecular weight cutoff filter (Fig. 1a). To
ensure ultrapure samples free of any residual soluble proteins,
the exosomes were further purified by size exclusion chroma-
tography (SEC). A typical elution profile is depicted in
Fig. 1b, showing a small but well-resolved peak around
12.5ml elution volume originating from the optical absorption
at 280 nm of exosomal proteins. Soluble, non-exosomal pro-
teins are eluted at larger elution volumes as broader peaks.
Cryo-electron microscopy (cryo-EM) micrographs revealed
well-preserved purified exosomal vesicles with closed circular
lipid bilayers comprising densely packed membrane proteins
and clean of any large contaminants (Fig. 1c). The size distri-
bution of the purified vesicles, determined by dynamic light
scattering (DLS), ranged from 30 to 200 nm (Fig. 1d), in good
agreement with data published elsewhere [31].
Functionalization of the immunosensor surface
To characterize the molecular identity of the biomarkers on the
exosomal membrane, the SPR sensor surface must
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specifically bind the target analyte and sustain a stable signal.
Our surface modification strategy is based on: (i) passivation
with polyethylene glycol (PEG) polymers, which efficiently
suppress nonspecific binding [32], and (ii) functionalization
with neutravidin, which forms on the sensor surface a strong
and long-lasting complex with biotinylated antibodies [33]
(Fig. 2a). The gold surface was first modified with a self-
assembled monolayer composed of a 99:1 M ratio of short
and long carboxylated PEGs which drastically reduced the
nonspecific binding (Fig. 2c). After activation of the surface-
accessible carboxyl groups and the subsequent covalent at-
tachment of the amino groups of neutravidin, the sensor sur-
face was functionalized with biotinylated antibodies (Fig. 2b
and ESM Table S1). This functionalization procedure is ide-
ally suited to produce a stable and robust baseline signal with
no loss of capturing agents. The thus prepared sensor surface
efficiently captures exosomes with high specificity as demon-
strated by the negligible response (<3 %) for a control anti-
body (Fig. 2c). This surface modification combined with the
microfluidic system of the SPR instrument made it possible to
test a panel of capturing agents in parallel with minimum
sample volumes (20 μl). Thereafter, we screened the
exosomes for the presence of two exosomal markers, CD63
and CD9, which are transmembrane proteins of the tetraspanin
family [34] and four cancer markers CD24, CD44, epithelial
cell adhesion molecule (EpCAM), and human epidermal
growth factor receptor 2 (HER2). The progression of many
tumors are reflected in a modification of the expression of
CD44 versus CD24 [35, 36], while EpCAM and HER2 are
often expressed preferentially in breast cancer cells and are
therefore used to subdivide breast cancer into subtypes to
fine-tune therapies [37].
Molecular screening of exosomes
We first performed our molecular screening on exosomes shed
by MCF-7 cells, knowing that this particular cell line is rep-
resentative of the breast cancer subtype luminal A [30].
Fig. 1 Purification of exosomes derived from breast cancer cell lines. A
Typical workflow for the isolation, enrichment, purification, and analysis
of exosomes from conditioned medium. The combination of UF and SEC
produces ultrapure upconcentrated samples of exosomes. Screening of
exosomes across a panel of antibodies is performed by SPR. B SEC
elution profile of an ultrafiltrated CM of MCF-7 cells. The absorbance
was measured at 280 nm, reflecting the amount of protein content. The
exosomal fraction appeared between 11 and 14 ml elution volume. C
Cryo-EM micrograph of an exosome secreted by MCF-7 cells. Scale
bar 50 nm. D Size distribution of MCF-7 exosomes obtained by DLS
Fig. 2 SPR analysis of exosomes.A Scheme of the functionalization of the
SPR sensor surface. The sensor surface was first passivated with a mixture
of short and long carboxylated PEGs to which neutravidin was covalently
bound, followed by functionalization with biotinylated antibodies. B
Typical SPR sensorgram of the sensor chip functionalization. Neutravidin
is attached to the surface using standard amine coupling chemistry to
subsequently capture the biotinylated antibodies. C Specific detection of
MCF-7 exosomes with biotinylated anti-CD44 antibodies (solid line).
Anti-rat IgG1 was used as a negative control (dashed line)
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Typical MCF-7 exosomes binding on the immunosensor
chip are presented in Fig. 3a. The observed variation in
responses across the panel of antibodies provides evi-
dence of the capacity of our sensor to detect and quan-
tify proteins on the surface of exosomes. The expression
profile of the corresponding antigens was obtained by
taking into consideration the respective antibody surface
coverage and assuming similar binding affinities of the
different antibodies (inset of Fig. 3a). Interestingly,
exosomal markers, CD63 and CD9, and cancerous
markers, CD44 and CD24, exhibited a similar expres-
sion level while EpCAM was significantly less abundant
on the surface of exosomes. On the opposite, antibodies
anti-HER2 were totally inefficient to capture exosomes
as expected by the molecular pattern of this breast can-
cer cell line [30]. These observations were confronted
with those obtained with standard enzyme-linked immu-
nosorbent assay (ELISA, ESM Figure S1A), which pro-
v ided a compar ab l e molecu l a r p ro f i l e (ESM
Figure S2A). However, we note a discrepancy for
CD24 which might be explained by the lack of surface
coverage control inherent to ELISA. Moreover, ELISA
required numerous handling steps and incubation times
which delay the analysis and might increase the vari-
ability among and within samples. As exosomes of dif-
ferent origins presumably vary in their membrane pro-
tein expression profile, we tested two other breast can-
cer cell lines as a source of exosomes, MDA-MB-231
and BT-474. SPR can provide precise information on
the exosome production and concentration through the
responses obtained with ubiquitous exosome markers
[27, 29]. Hence, the signal arising from exosome bind-
ing to anti-CD63 antibodies was used here as a real-
time standard calibration reflecting the quantity of
injected exosomes, circumventing any errors originating
from batch-to-batch variation (Fig. 3b). The various re-
sponses between the different exosomes and the
immunosensor surfaces formed specific molecular signa-
tures which are graphically represented in the color-
coded table of Fig. 3c; CD63 response was used as a
normalization factor between exosomes preparations.
Exosomes derived from MDA-MB-231 cells were ob-
served to be enriched in CD44 molecules which reflect
their cellular origin. Surprisingly, antibodies against
HER2 failed to capture exosomes shed by BT-474 cells,
a member of luminal B cancer subtype and known to
express HER2. This demonstrates either a poor affinity
of this antibody against this receptor or ultimately the
exclusion of this antigen from the surface of exosomes.
Importantly, surfaces functionalized with antibodies
against EpCAM successfully discriminate exosomes de-
rived from MDA-MB-231 from those isolated from
MCF-7 and BT-474. This result corroborates previous
observations where MCF-7 and BT-474 cells were
shown to express more of this antigen [38] and demon-
strates the effectiveness of our molecular profiling.
Analysis of blood samples
The clinical applicability and usability of our procedure,
which consists of exosome purification and antibody screen-
ing, were assessed by analyzing plasma samples obtained
from healthy donors. Since exosomes are naturally found in
blood in very high numbers (108–1011 per mL) [9, 39, 40],
0.5 mL of blood plasma contains sufficient exosomes to per-
form a complete screening of antibodies by SPR. We used the
Fig. 3 Molecular screening of exosomes with immunosensor chips. A
Multiplexed analysis of MCF-7 exosome membrane proteins by SPR.
The sensorgrams display the capture of exosomes with a panel of
antibody: anti-CD63, anti-CD9, anti-CD44, anti-CD24, anti-EpCAM,
and anti-HER2. The inset shows the relative expression profile of the
antigens. B Specific binding of MDA-MB-231, MCF-7, and BT-474
exosomes to anti-CD63 antibody. CMolecular profiling of breast cancer
and exosomal biomarkers in exosomes derived from the three breast
cancer cell lines, MDA-MB-231, MCF-7 and BT-474. Sensorgrams in
A andBwere corrected for bulk refractive index changes and nonspecific
binding
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aforementioned isolation protocol, except that the plasma
was not concentrated by UF. Briefly, the plasma was first
centrifuged and filtered to remove cells, cell debris, and
large particles and then injected into the SEC column.
Compared to classical procedures using differential ultracen-
trifugation [41], this methodology offers several advantages
for the isolation of exosomes from biofluids, especially from
blood derived samples: (i) the purified exosomes retain their
morphological integrity without aggregating as demonstrat-
ed by cryo-EM (Fig. 4a) and DLS (ESM Figure S2A), (ii)
they are separated from lipoproteins and protein aggregates
[42], and moreover, (iii) the overall procedure is performed
within less than 30 min. The plasma exosomes were then
analyzed by SPR. Our immunosensor chips proved
again to be highly efficient to suppress nonspecific
binding (ESM Figure S2B) and enabled the complete
molecular biomarker screening (Fig. 4b). Although no
conclusion regarding the clinical relevance of these data
could be drawn, the particular expression pattern of this
sample not only describes the membrane protein profile
of a single population but also reflects the complexity
of the entire blood exosomal population (Fig. 4c).
Exosomes are mainly derived from blood cells (erythro-
cytes, leukocytes, and thrombocytes) and, to a lower
extent, from other cell tissues (epithelial, nervous, muscle, or
connective tissues). During the progression of cancer,
exosomes derived from the diseased cells are released into
biofluids, in particular blood, and thus modify the molecular
profile of the exosomal population as they carry the molecular
identity of the tumor [43]. Hence, the systematic implementa-
tion of our method on exosomes isolated from body fluids of
both cancer patients and healthy donors, whose medical-
related characteristics are known (e.g., age, sex, type, stage,
and prognosis of the disease), would potentially link unique
molecular signatures to particular types and stages of cancer.
This novel strategy coupled to the isolation and purification of
exosomes from body fluids would pave the way for a remote
non-invasive and label-free diagnostic and prognostic test in
cancer disease.
Conclusion
We offer here an attractive alternative to the conventional label-
based immunoassays for the rapid, multiplexed protein profiling
of exosomes.While SPR techniques are generally used to detect
small molecules or proteins, the large molecular mass
of exosomes generate large signals even in SPR devices of
simple optical design. Therefore, this technique offers enhanced
detection sensitivity over competing standard techniques,
circumventing the need of large sample volume. The combina-
tion of label-free and real-time detection of SPR provides
fast analysis and minimizes tedious and time-consuming
handling steps. We showed for the first time that exosomes
from human blood could be purified and analyzed in less
than 1 h using a commercially available instrument, offer-
ing a standard procedure for the development of a point-of-
care patient sample analysis. The sensor architecture opens
the door for clinicians to detect cancer-specific exosomes
in a fully automated format using microliter volumes of
blood. The immunosensor chip would provide easy, fast,
minimally invasive, and continuous access to the state of
tumors and therefore open a novel way in cancer diagnosis
and personalized medicine without injuring the patients.
The easy-to-prepare and easy-to-use sensor design offers
the possibility to diagnose multiple cancer types with a
single instrument.
Fig. 4 Characterization and molecular analysis of exosomes isolated
from human blood plasma. A Four cryo-EM micrographs of purified
exosomes. Scale bar, 50 nm. B Multiplexed SPR analysis of membrane
proteins in exosomes. The sensorgrams display the capture of exosomes
with a panel of antibody: anti-CD63, anti-CD9, anti-CD44, anti-CD24,
anti-EpCAM, and anti-HER2. Sensorgrams were corrected for bulk
refractive index changes and nonspecific binding. C Relative expression
profile of the antigens on the surface of plasma exosomes
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